Alkermes reports positive phase 1b results for ADHD drug ALKS 7290

September 21, 2026 7:00 AM

Alkermes plc (Nasdaq: ALKS) announced positive topline results from a phase 1 proof-of-concept study of ALKS 7290, an investigational oral ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found